Domov › Kolorektálny karcinóm › Texas
Klinické štúdie Kolorektálny karcinóm v štáte Texas
145 štúdií pre Kolorektálny karcinóm hľadá účastníkov v zariadeniach v štáte Texas.
Mestá v štáte Texas
- Houston102 štúdií
- San Antonio46 štúdií
- Dallas33 štúdií
- Austin19 štúdií
- Irving13 štúdií
- Tyler8 štúdií
- Fort Worth7 štúdií
- League City6 štúdií
- Killeen6 štúdií
- Abilene5 štúdií
- The Woodlands5 štúdií
- Lewisville3 štúdií
- Round Rock3 štúdií
- Arlington3 štúdií
- Amarillo3 štúdií
Oficiálny text štúdie (anglicky)
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
- Texas Oncology - Abilene - Antilley Road /ID# 280120, Abilene
- The University of Texas MD Anderson Cancer Center /ID# 279865, Houston
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT07525206The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- New Experimental Therapeutics - NEXT Oncology, Austin
- Texas Oncology, Bedford
- UT Southwest Simmons Cancer Center, Dallas
- a 2 ďalších
Prebieha náborFáza 1/2
Vek 12 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT04585750A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- NEXT Austin, Austin
- START Center for Clinical Research, Fort Worth
- University of Texas MD Anderson Cancer Center, Houston
- a 1 ďalších
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT06270706Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- The Don and Sybil Harrington Cancer Center, Amarillo
- UT MD Anderson Cancer Center, Houston
- Audie L Murphy VA Hospital, San Antonio
Prebieha náborObservačná štúdiaVítaní zdravých dobrovoľníkov
Vek 40 až 75 · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT05334069A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT06760819Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #46, Austin
- Exelixis Clinical Site #89, Dallas
- Exelixis Clinical Site #73, Irving
- a 2 ďalších
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 1. 10. 2026 · NCT05176483177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- MD Anderson Cancer Center, Houston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 1. 10. 2026 · NCT07189871Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- SCRI at Mary Crowley, Dallas
- University of Texas Southwestern Medical Center, Dallas
- The University of Texas MD Anderson Cancer Center, Houston
- a 1 ďalších
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 1. 10. 2026 · NCT06625775Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- The Methodist Hospital Research Institute, Houston
- The University of Texas MD Anderson Cancer Center, Houston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 30. 9. 2026 · NCT06324357A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
- ALX Center 5, Houston
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 30. 9. 2026 · NCT07085091Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial
- UT MD Anderson Cancer Center, Houston
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 29. 9. 2026 · NCT07551596A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Houston
- Research Site, Round Rock
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 29. 9. 2026 · NCT05877599A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
- START Dallas Fort Worth, Fort Worth
- The University of Texas MD Anderson Cancer Center, Houston
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 29. 9. 2026 · NCT07659795A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
- NEXT Dallas, Irving
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 29. 9. 2026 · NCT07578571A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
- Texas Oncology - Austin Midtown /ID# 271354, Austin
- Texas Oncology - Deke Slayton Cancer Center /ID# 271355, Webster
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT06820463Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- Texas Oncology - West Texas, Abilene
- Texas Oncology - West Texas, Amarillo
- Texas Oncology - Gulf Coast, Beaumont
- a 27 ďalších
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT07222800Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
- MD Anderson Cancer Center, GI Medical Oncology Dept, Houston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT05482893A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
- University of Texas MD Anderson Cancer Center ( Site 0316), Houston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06428409A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
- MD Anderson Cancer Center, Houston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT05379595A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
- GSK Investigational Site, Dallas
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT07277270Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Research Site, Dallas
- Research Site, Galveston
- Research Site, Houston
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06218914A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
- MD Anderson Cancer Center, Houston
- START San Antonio, San Antonio
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06004245A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
- Texas Oncology West Texas, Abilene
- Parkland Health and Hospital System, Dallas
- Texas Oncology DFW, Dallas
- a 6 ďalších
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06750094A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- Texas Oncology West Texas, Abilene
- Texas Oncology DFW, Dallas
- UT Southwestern, Dallas
- a 4 ďalších
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06662786Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- a 2 ďalších
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 24. 9. 2026 · NCT05863195Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Baylor, Scott and White Research Institute, Dallas
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 24. 9. 2026 · NCT06047379A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
- Texas Oncology Dallas Fort Worth West (DFWW) - Arlington Cancer Center North, Arlington
- Texas Oncology, PA, Austin
- Baylor College of Medicine Medical Center, Houston
- a 1 ďalších
Prebieha náborFáza 2/3
Vek 18 a viac · Všetky pohlavia · Aktualizované 23. 9. 2026 · NCT07221357Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Houston
Prebieha náborFáza 2
Vek 18 až 130 · Všetky pohlavia · Aktualizované 23. 9. 2026 · NCT05489211Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
- UT MD Anderson Cancer Center, Houston
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 23. 9. 2026 · NCT06102902Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- MD Anderson, Houston
- NEXT Dallas, Irving
- NEXT Oncology San Antonio, San Antonio
- a 1 ďalších
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT06128551A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Texas Oncology - DFW (Sammons CC), Dallas
- MD Anderson Cancer Center, Houston
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT07114601Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- Baylor College of Medicine, Houston
- The University of Texas MD Anderson Cancer Center, Houston
- NEXT Oncology Dallas, Irving
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT06445062A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Texas Oncology - DFW (Sammons CC), Dallas
- Baylor College of Medicine, Houston
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT07213791A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer
- NEXT Houston, Houston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 21. 9. 2026 · NCT07693751A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 21. 9. 2026 · NCT07629960Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- NEXT - Dallas, Dallas
- NEXT, San Antonio
- START - San Antonio, San Antonio
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 17. 9. 2026 · NCT07349537Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- MD Anderson Cancer Center, Houston
- START San Antonio, San Antonio
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 16. 9. 2026 · NCT05786924A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
- Ascension Seton Spclty Care Ctr, Austin
- Texas Oncology, Austin
- University of Texas Southwestern Medical Center, Dallas
- a 2 ďalších
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 15. 9. 2026 · NCT07284849A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
- Texas Oncology - Northeast Texas, Denton
- Texas Oncology - Gulf Coast, Webster
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 11. 9. 2026 · NCT04929223Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
- M D Anderson Cancer Center, Houston
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 11. 9. 2026 · NCT05985954Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.